

<b>General information about company</b>	
Name of The Company	LINCOLN PHARMACEUTICALS LTD
BSE Scrip Code	531633
NSE Symbol	LINCOLN
MSE Symbol	NOTLISTED
Date of Start of Financial Year	01-04-2021
Date of End of Financial Year	31-03-2022
Reporting Period	First half yearly
Date of Start of Reporting Period	01-04-2021
Date of End of Reporting Period	30-09-2021
Level of rounding used in financial results	Lakhs
Whether the company has entered into any Related Party transaction during the selected half year for which it wants to submit disclosure?	Yes

		Sr	1	2	3	4	5	6	7
<b>A. Details of related party</b>		Name of the related party	Amar A. Patel	Anand A. Patel	Aniruddh H. Patel	Arvindbhai G. Patel	Ashish R. Patel	Ashish R. Patel-HUF	Darshit A. Shah
		Categories of related parties	Promoters Group	Promoters Group	Promoters Group	Key management personnel of entity or parent	Key management personnel of entity or parent	Entities with joint control or significant influence over entity	Key management personnel of entity or parent
		description of relationship	Relative of Key management personnel of entity	Relative of Key management personnel of entity	Relative of Key management personnel of entity	Director of entity	Whole Time Director of entity	Controlled by Key management personnel of entity	Chief Financial Officer of entity
		PAN of related party	ACKPP9280F	AGAPP0508J	AKHPP8794P	AGWPP5494P	AGAPP6089Q	AAHHA8124L	BSTPS9062.
		CIN of related party							
<b>B. Details of related party transactions</b>	Purchase of goods and services								
	Sale of goods and services								
	Purchase of fixed assets								
	Sale of fixed assets								
	Rendering of services					4.2		23.6	
	Receiving of services								
	Leases								
	Loans and advances given								
	Loans and advances taken								
	Loans and advances given that are repaid								
	Loans and advances taken that are repaid								
	Deposits placed								
	Deposits taken								
	Transfer of research & development								
	Transfers under lease agreement								
	Equity investment								
	Impairment in equity investment								
	Expense for bad or doubtful debts								
Guarantees or collateral									

		given							
		Guarantees or collateral taken							
		Interest income							
		Interest paid							
		Dividend income							
		Dividend paid	0.9	2.73	1.0305	1.665	15.01203		
		Management contracts including for deputation of employees							
		Settlement of liabilities by entity on behalf of related party							
	<b>Remuneration</b>		Short term employee benefits		7.03974			21.9612	5.17254
			Post employment benefits						
		Other long-term benefits							
		Termination benefits							
		Share based payments							
		Others							
<b>C. Outstanding balances</b>	<b>Receivables</b>	Secured							
		Un Secured							
	<b>Payables</b>	Secured							
		Un Secured							
	<b>Loans and advances</b>	Secured							
		Un Secured							
	<b>given Loans and advances</b>	Secured							
		Un Secured							
	<b>taken Deposits placed</b>	Secured							
		Un Secured							
	<b>Deposits taken</b>	Secured							
		Un Secured							
	<b>Guarantees or collateral</b>	Secured							
		Un Secured							
	<b>given Guarantees or collateral</b>	Secured							
		Un Secured							
	<b>taken Investment in equity</b>	Secured							
		Un Secured							
	<b>Provision for doubtful debt</b>	Secured							
		Un Secured							
<b>Note</b>									

